Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. 2007

K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Kraków, Poland. stachow@if-pan.krakow.pl

The purpose of the present study was to investigate whether the anxiolytic-like action of a selective and brain penetrable group I metabotropic glutamate (mGlu5) receptor antagonist 3-[(2-methyl-1,3-tiazol-4-yl)ethynyl]-pyridine (MTEP) is dependent upon the serotonergic system. Experiments were performed on male Wistar rats. The Vogel conflict drinking test was used to detect anxiolytic-like activity. MTEP administered intraperitoneally at doses of 1, 3 and 6 mg/kg induced anxiolytic-like effect. The potential anxiolytic effect of MTEP (1 mg/kg) was inhibited by a nonselective 5-HT receptor antagonist metergoline (2 mg/kg i.p.) and 5-HT2A/2C receptor antagonist ritanserin (0.5 mg/kg i.p.), but not by a 5-HT1A receptor antagonist N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridynyl)cyclohexane-carboxamide (WAY 100635) (0.1 mg/kg i.p). The anxiolytic effect of MTEP (6 mg/kg) was attenuated by ritanserin (1 mg/kg i.p.). Moreover, MTEP-induced a dose-dependent release of serotonin in the frontal cortex. The obtained results suggest that the potential anxiolytic effect of the mGlu5 receptor antagonist MTEP is due to the increased serotonin release with subsequent activation of 5-HT2A/2C receptors, most probably located postsynaptically, but not by the 5-HT1A receptors.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008297 Male Males
D008711 Metergoline A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy. Methergoline,Liserdol
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine

Related Publications

K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
October 2010, Behavioural pharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
December 2006, Progress in neuro-psychopharmacology & biological psychiatry,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
January 1987, Psychopharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
March 2003, European journal of pharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
January 2008, Physiology & behavior,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
January 2014, Psychopharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
May 1992, Japanese journal of pharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
December 1998, Neuropharmacology,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
February 1999, Biulleten' eksperimental'noi biologii i meditsiny,
K Stachowicz, and K Gołembiowska, and M Sowa, and G Nowak, and E Chojnacka-Wójcik, and A Pilc
July 2011, Bulletin of experimental biology and medicine,
Copied contents to your clipboard!